At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 17 enrolled
Drug / intervention
Sucroferric Oxyhydroxide Chewable Tabletdrug
Likely dose
Sucroferric Oxyhydroxide Chewable Tablet 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
In Brief
A Phase 4 clinical trial evaluating Sucroferric Oxyhydroxide Chewable Tablet for Peritoneal Dialysis Complication and 2 related conditions. Completed, enrolled 17 participants across 1 site.
Detailed Summary
Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartFeb 2020
Primary CompletionJul 2021
TodayJul 2026
First PostedAug 6, 2019
Enrollment StartFeb 1, 2020
Primary CompletionJul 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.9 years ago
Interventions
Sucroferric Oxyhydroxide Chewable Tabletdrug
Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal